GoCART
GoCART Therapeutics is building a new generation of safer, smarter cell therapies for cancer. Our technology uses a biological 'AND-gate'—a two-key safety system that only activates its 'kill' signal when it detects two distinct targets on a cancer cell. This logic-gated approach dramatically reduces the toxicity risks of current CAR-T therapies.
Community Sentiment
How do you feel about this ipt?
Community Sentiment
How do you feel about this ipt?
Project
Market Overview
Summary
GoCART is developing advanced cancer therapies that activate only when multiple tumor signals are present, aiming to target cancer more precisely and reduce harmful side effects for patients.
Problem
Current CAR-T cancer therapies can attack healthy cells and miss tumors, causing dangerous side effects, limited effectiveness and leaving many types of cancer without an option for therapy. We aim to make these treatments safer, more precise, and adaptable for more patients.
Impact
GoCART is pioneering safer, smarter CAR-T therapies with logic-gated precision, aiming to set a new standard in cancer treatment and prove the power of decentralized science to accelerate life-saving innovation.
Market Overview
Summary
GoCART is developing advanced cancer therapies that activate only when multiple tumor signals are present, aiming to target cancer more precisely and reduce harmful side effects for patients.
Problem
Current CAR-T cancer therapies can attack healthy cells and miss tumors, causing dangerous side effects, limited effectiveness and leaving many types of cancer without an option for therapy. We aim to make these treatments safer, more precise, and adaptable for more patients.
Impact
GoCART is pioneering safer, smarter CAR-T therapies with logic-gated precision, aiming to set a new standard in cancer treatment and prove the power of decentralized science to accelerate life-saving innovation.
This project generates value by enabling community-driven funding for research and development, specifically targeting the achievement of a validated in vitro proof-of-concept. By reaching this milestone, the project creates a high-value intellectual property asset that can be licensed to industry partners, unlocking significant downstream revenue opportunities.
The $GCART IP-token allows supporters to participate in the creation and future value of this IP. Token utility and project sustainability are further enhanced by the Bio Protocol V2 Launchpad, which allocates a portion of trading fees directly to the R&D treasury. This mechanism ensures ongoing, non-dilutive funding for research, aligning incentives between the community and the project's long-term success.
AI Trimer Generation
In Silico design with Genki IT
Binder Discovery
VHH generation with ONCERA/WuXi
Candidate Optimization
Finalizing 1–4 trimer candidates
CAR Vector Establishment
Retroviral vector design & delivery
Foundational Patents
Filing IP for Trimer sequence composition
In Vitro Validation
Primary Proof-of-Concept via cytotoxicity assays
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
https://doi.org/10.1158/2159-8290.cd-23-0101
Scientists are making CAR-T cells more clever. Here’s what the next generation could look like
https://www.statnews.com/2022/01/14/cancer-cart-cell-therapy-research/
Virtual Event: CAR-T comes of age?
https://www.statnews.com/2021/10/14/virtual-event-car-t-comes-of-age/
Switchable’ CAR-T startup raises $112 million
https://www.statnews.com/2024/10/22/biotech-news-pfizer-eli-lilly-avencell-editas-car-t-takeda-biomarin-the-readout/
CAR T-cell Therapy for Multiple Myeloma
https://www.cancer.org/cancer/types/multiple-myeloma/treating/car-t-cell-therapy.html
Patient-reported efficacy and toxicity in CAR T-cell therapy for multiple myeloma via Internet-based platforms
https://www.asco.org/abstracts-presentations/ABSTRACT340495
Community
Stay up to date
Get the latest community updates and find out about upcoming GoCART developments
